Dihydroergotamine
Small molecule targets HTR1D via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | D.H.E. 45 | — | 1946-04-12 | fda.gov ↗ |
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07665892 | May → Dec 2026 expected | — | Aspeya, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05351086 | Jun → Sep 2022 | — | Pulmatrix Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03874832 | Sep → Nov 2018 | migraine with aura, migraine without aura | Satsuma Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01191723 | Aug → Sep 2010 | — | Allergan | Completed | No outcome recorded |
| Phase 1 | NCT01468558 | Jul → Aug 2010 | — | Allergan | Completed | No outcome recorded |
| Phase 1 | NCT01089062 | Mar → Sep 2010 | — | Allergan | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01199965 | Jan → Apr 2010 | — | Allergan | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07646613 | May → Dec 2026 expected | migraine disorder | Aspeya, Inc. | Recruiting | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT04940390 | Jun 2021 → Oct 2022 | migraine with aura, migraine without aura | Satsuma Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02706015 | Oct 2020 → May 2021 | migraine disorder | Ache Laboratorios Farmaceuticos S.A. | Withdrawn | No outcome recorded |
| Phase 3 | NCT04406649 | Sep 2020 → Jan 2023 | migraine with aura, migraine without aura | Satsuma Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02582996 | Apr 2020 → Apr 2021 | migraine disorder | Ache Laboratorios Farmaceuticos S.A. | Suspended | No outcome recorded |
| Phase 3 | NCT03901482 | Jun 2019 → Jul 2020 | migraine with aura, migraine without aura | Satsuma Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03557333 | Jul 2018 → Mar 2020 | migraine disorder | Impel Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00623636 | Jul 2008 → Dec 2010 | migraine disorder | Allergan | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00335777 | Aug 2006 → Dec 2008 | migraine disorder | Thomas Jefferson University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00203268 | Dec 2003 → Mar 2005 | migraine disorder | Thomas Jefferson University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07226362 Comparator | Jun → Oct 2025 | — | Aspeya Switzerland SA | Completed | No outcome recorded |
| Phase 1 | NCT05337254 Comparator | Mar → Jun 2021 | migraine with aura, migraine without aura | Satsuma Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03401346 Comparator | Oct → Dec 2017 | migraine disorder | Impel Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03885154 Comparator | Oct 2017 → Mar 2019 | migraine disorder | Kimberly S Jones | Terminated | No outcome recorded |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dihydroergotamine | “ASY202 is a pre-metered drug-device combination product containing a dry-powder formulation of dihydroergotamine (DHE) intended for oral inhalation, delivered via a dry powder...” NCT07646613 ↗15“ASY202 is a pre-metered drug-device combination product containing a dry-powder formulation of dihydroergotamine (DHE) intended for oral inhalation, delivered via a dry powder...” NCT07665892 ↗ “Dihydroergotamine Mesylate (DHE) administered using the I123 Precision Olfactory Delivery (POD) Device” NCT03557333 ↗ “MAP0004 is an orally inhaled formulation of dihydroergotamine delivered to the systemic circulation.” PMID 21457235 ↗ Apr 2011 “Dihydroergotamine Mesylate (DHE) Delivered by Oral Inhalation (MAP0004)” NCT01468558 ↗ “Dihydroergotamine mesylate+ dipyrone sodium + caffeine” NCT02706015 ↗ “Dihydroergotamine Mesylate (DHE)” NCT01089062 ↗ |
| Known as | 9,10-dihydroergotamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1732 ↗ |
| Known as | DHE | “OBJECTIVE: To investigate and compare the safety and the pharmacokinetics of dihydroergotamine (DHE) after administration of intranasal DHE powder (STS101), intranasal DHE...” PMID 31985049 ↗ Jan 202013“An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesylate (DHE) Delivered Intravenously (DHE 45) and by...” NCT01199965 ↗ “STS101 is an investigational drug-device combination comprising 5.2 mg dihydroergotamine (DHE) powder (6.0 mg DHE mesylate) in a single-use nasal delivery device for the acute...” PMID 39373843 ↗ Oct 2024 “ASY202 is a pre-metered drug-device combination product containing a dry-powder formulation of dihydroergotamine (DHE) intended for oral inhalation, delivered via a dry powder...” NCT07646613 ↗ “ASY202 is a pre-metered drug-device combination product containing a dry-powder formulation of dihydroergotamine (DHE) intended for oral inhalation, delivered via a dry powder...” NCT07665892 ↗ “OBJECTIVE: MAP0004 is an investigational product which delivers dihydroergotamine (DHE) through the lung via a breath-synchronized metered dose inhaler.” PMID 23926420 ↗ Jul 2013 “Single dose 1.45 mg Dihydroergotamine Mesylate (DHE), administered by I123 Precision Olfactory Delivery (POD) device nasal spray (INP104)” NCT03401346 ↗ “Single Doses of Dihydroergotamine Mesylate (DHE) Inhalation Powder, DHE Intravenous (IV), and DHE Nasal Spray in Healthy Adult Subjects.” NCT07226362 ↗ “Dihydroergotamine Mesylate (DHE) administered using the I123 Precision Olfactory Delivery (POD) Device” NCT03557333 ↗ “MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.” PMID 21457235 ↗ Apr 2011 “Dihydroergotamine Mesylate (DHE) Delivered by Oral Inhalation (MAP0004)” NCT01468558 ↗ “Dihydroergotamine (DHE) will be given as weight-based dosing” NCT03885154 ↗ “intravenous (IV) dihydroergotamine (D.H.E) or IV placebo” NCT05351086 ↗ “intranasal dihydroergotamine (DHE) powder (STS101)” PMID 38413540 ↗ Feb 2024 |
| Known as | DHE-45 | “An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesylate (DHE) Delivered Intravenously (DHE 45) and by...” NCT01199965 ↗1“dihydroergotamine mesylate (DHE-45).” NCT00203268 ↗ |
| Known as | Diergo | ChEMBL registry synonym — accepted as the source's own label CHEMBL1732 ↗ |
| Known as | Dihidroergotamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1732 ↗ |
| Known as | Dihydergot | ChEMBL registry synonym — accepted as the source's own label CHEMBL1732 ↗ |
| Known as | Dihydroergotamine mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1732 ↗ |
| Known as | Dihydroergotamine Mesylate | “An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesylate (DHE) Delivered Intravenously (DHE 45) and by...” NCT01199965 ↗6“Single dose 1.45 mg Dihydroergotamine Mesylate (DHE), administered by I123 Precision Olfactory Delivery (POD) device nasal spray (INP104)” NCT03401346 ↗ “Single Doses of Dihydroergotamine Mesylate (DHE) Inhalation Powder, DHE Intravenous (IV), and DHE Nasal Spray in Healthy Adult Subjects.” NCT07226362 ↗ “Dihydroergotamine Mesylate (DHE) administered using the I123 Precision Olfactory Delivery (POD) Device” NCT03557333 ↗ “Dihydroergotamine Mesylate (DHE) Delivered by Oral Inhalation (MAP0004)” NCT01468558 ↗ “Dihydroergotamine Mesylate (DHE)” NCT01089062 ↗ |
| Known as | Dihydroergotamine mesylate component of embolex | ChEMBL registry synonym — accepted as the source's own label CHEMBL1732 ↗ |
| Known as | Dihydroergotamine methanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1732 ↗ |
| Known as | MAP0004 | “An Open-Label, 2-Period, Crossover Phase 2 Study Comparing the Pharmacokinetics and Tolerability of Dihydroergotamine Mesylate (DHE) Delivered Intravenously (DHE 45) and by...” NCT01199965 ↗ |
| Known as | Migranal | “OBJECTIVE: To investigate and compare the safety and the pharmacokinetics of dihydroergotamine (DHE) after administration of intranasal DHE powder (STS101), intranasal DHE...” PMID 31985049 ↗ Jan 2020 |
| Known as | Neomigran | ChEMBL registry synonym — accepted as the source's own label CHEMBL1732 ↗ |
| Known as | NSC-759848 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1732 ↗ |
| Known as | STS101 | “OBJECTIVE: To investigate and compare the safety and the pharmacokinetics of dihydroergotamine (DHE) after administration of intranasal DHE powder (STS101), intranasal DHE...” PMID 31985049 ↗ Jan 20201“intranasal dihydroergotamine (DHE) powder (STS101)” PMID 38413540 ↗ Feb 2024 |
| Known as | Tonopan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1732 ↗ |
| Known as | Trudhesa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1732 ↗ |
| Action | Activate | “Serotonin 1d (5-HT1d) receptor agonist” CHEMBL1732 ↗ |
| Modality | Small molecule | — CHEMBL1732 ↗ |
| Route | Intranasal | “The study drug is a medication that is taken in the form of nasal spray.” NCT00335777 ↗ |
| Target | HTR1D | “Serotonin 1d (5-HT1d) receptor agonist” CHEMBL1732 ↗ |